Document Detail


Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate.
MedLine Citation:
PMID:  8530584     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Bisphosphonates are used with increasing frequency in the treatment of patients with osteoporosis. Continuous administration of low doses of nitrogen-containing bisphosphonates by mouth is the preferred mode of therapy. The skeletal half-life of bisphosphonates is long, however, and little is known about their long term effects on skeletal metabolism. We examined the changes in biochemical parameters of bone turnover [serum alkaline phosphatase and urinary hydroxyproline (OHP)], in bone mineral density, and in fracture frequency after discontinuation of long term (mean, 6.5 yr, range, 5-9 yr) therapy with oral pamidronate (150 mg/day) in 30 patients with osteoporosis and vertebral fractures. Serum alkaline phosphatase and urinary OHP were significantly lower at the end of long term treatment (90% and 72% of basal values, respectively). Serum alkaline phosphatase had increased to basal values within 6 months of stopping treatment, whereas OHP increased significantly to a maximum average of 92% of pretreatment values. There was no change in the every 6-month bone mineral density measurements of the lumbar spine and the femoral neck during the 2 yr after stopping treatment. Spine fracture index, calculated by the method of Raymakers and co-workers, was 0.83 +/- 0.12 before treatment, 0.85 +/- 0.12 at the end of treatment, and 0.85 +/- 0.13 2 yr after stopping treatment (nonsignificant). There was also no significant change in the rate of new vertebral fractures on or up to 2 yr after stopping treatment (48.5 of 1000 and 46.5 of 1000 patient yr, respectively). Our data demonstrate that the sustained suppression of bone turnover induced by long term treatment with pamidronate is readily reversible on stopping treatment. The beneficial effect of this treatment regimen on the skeleton, however, appears to be maintained for at least 2 yr after discontinuation of treatment.
Authors:
J O Landman; N A Hamdy; E K Pauwels; S E Papapoulos
Related Documents :
10510214 - Goals of treatment for paget's disease of bone.
23490474 - Effect of remifentanil on the hemodynamic responses and recovery profile of patients un...
8883124 - Estrogen replacement may be an alternative to parathyroid surgery for the treatment of ...
20082084 - Presence of subchondral bone marrow edema at the time of treatment represents a negativ...
6509994 - Long-term results of coronary surgery.
12190674 - Randomized clinical trial of specific lactobacillus and fibre supplement to early enter...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of clinical endocrinology and metabolism     Volume:  80     ISSN:  0021-972X     ISO Abbreviation:  J. Clin. Endocrinol. Metab.     Publication Date:  1995 Dec 
Date Detail:
Created Date:  1996-01-31     Completed Date:  1996-01-31     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0375362     Medline TA:  J Clin Endocrinol Metab     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  3465-8     Citation Subset:  AIM; IM    
Affiliation:
Department of Endocrinology, University Hospital, Leiden, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Bone Density
Bone and Bones / metabolism*
Diphosphonates / administration & dosage*,  therapeutic use
Female
Femur Neck / metabolism
Follow-Up Studies
Humans
Incidence
Male
Middle Aged
Osteoporosis / complications,  drug therapy*,  metabolism*
Spinal Fractures / epidemiology,  etiology
Spine / metabolism
Time Factors
Chemical
Reg. No./Substance:
0/Diphosphonates; 40391-99-9/pamidronate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mechanism of renal calcium conservation with estrogen replacement therapy in women in early postmeno...
Next Document:  Body fat distribution and steroid hormone concentrations in obese adolescent girls before and after ...